Coan M H, Brockway W J, Eguizabal H, Krieg T, Fournel M
Vox Sang. 1985;48(6):333-42. doi: 10.1111/j.1423-0410.1985.tb00193.x.
Alpha 1-proteinase inhibitor (alpha 1-PI) has been prepared as a concentrate in quantities large enough for clinical testing of its safety and efficacy in the treatment of emphysema and other disorders. The alpha 1-PI was purified from Cohn fraction IV-1 paste by polyethylene glycol precipitation and DEAE-Sepharose chromatography. The methods used in the purification are gentle and the resulting product behaves almost identically to the alpha 1-PI from plasma. The protein has been heat treated (60 degrees C, 10 h) to lower the risk of transmission of plasma-borne diseases. This resulted in some aggregation of the protein, but did not cause the generation of new antigenic sites. Half-life studies in animals showed that the protein behaved normally (catabolic t1/2 of 68 h).
α1-蛋白酶抑制剂（α1-PI）已被制备成浓缩物，其数量足以用于临床测试其在治疗肺气肿和其他疾病方面的安全性和有效性。α1-PI通过聚乙二醇沉淀和DEAE-琼脂糖凝胶色谱从科恩IV-1组分糊剂中纯化得到。纯化过程中使用的方法较为温和，所得产品的行为与血浆中的α1-PI几乎相同。该蛋白质经过热处理（60℃，10小时）以降低血源性病原体传播的风险。这导致了蛋白质的一些聚集，但并未产生新的抗原位点。动物体内的半衰期研究表明该蛋白质表现正常（分解代谢半衰期为68小时）。
